<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: additional funding either through equity", fill: "#7c0a02"},
{source: "2: additional funding either through equity", target: "2: financings", fill: "#7c0a02"},
{source: "2: financings", target: "2: partnering arrangements", fill: "#7c0a02"},
{source: "2: partnering arrangements", target: "2: further dilutive", fill: "#7c0a02"},
{source: "2: further dilutive", target: "2: stockholders", fill: "#7c0a02"},
{source: "2: stockholders", target: "2: could negatively affect us", fill: "#7c0a02"},
{source: "2: could negatively affect us", target: "2: independent auditors", fill: "#7c0a02"},
{source: "2: independent auditors", target: "2: explanatory paragraph", fill: "#7c0a02"},
{source: "2: explanatory paragraph", target: "2: consolidated financial statements", fill: "#7c0a02"},
{source: "2: consolidated financial statements", target: "2: fiscal year", fill: "#7c0a02"},
{source: "2: fiscal year", target: "2: December ", fill: "#7c0a02"},
{source: "2: December ", target: "2: doubt about", fill: "#7c0a02"},
{source: "2: doubt about", target: "2: continue as", fill: "#7c0a02"},
{source: "2: additional funding either through equity", target: "3: current cash", fill: "#4166f5"},
{source: "3: current cash", target: "3: December ", fill: "#4166f5"},
{source: "3: December ", target: "3: January ", fill: "#4166f5"},
{source: "3: January ", target: "3: Senior Secured Notes ", fill: "#4166f5"},
{source: "3: Senior Secured Notes ", target: "3: enable us", fill: "#4166f5"},
{source: "3: enable us", target: "3: operations as", fill: "#4166f5"},
{source: "3: operations as", target: "3: until approximately", fill: "#4166f5"},
{source: "3: current cash", target: "11: enter into partnering", fill: "#aa381e"},
{source: "11: enter into partnering", target: "11: collaborative", fill: "#aa381e"},
{source: "11: collaborative", target: "11: arrangements", fill: "#aa381e"},
{source: "11: arrangements", target: "11: regardless", fill: "#aa381e"},
{source: "11: regardless", target: "11: additional funding", fill: "#aa381e"},
{source: "11: additional funding", target: "11: operations", fill: "#aa381e"},
{source: "11: enter into partnering", target: "13: difficult", fill: "#4f7942"},
{source: "13: difficult", target: "13: precisely predict", fill: "#4f7942"},
{source: "13: precisely predict", target: "13: future capital requirements as such requirements", fill: "#4f7942"},
{source: "13: future capital requirements as such requirements", target: "13: depend upon", fill: "#4f7942"},
{source: "13: depend upon", target: "13: clinical testing especially", fill: "#4f7942"},
{source: "13: clinical testing especially", target: "13: establish additional corporate partnerships", fill: "#4f7942"},
{source: "13: establish additional corporate partnerships", target: "13: manufacture", fill: "#4f7942"},
{source: "13: manufacture", target: "13: potential products", fill: "#4f7942"},
{source: "13: potential products", target: "13: development programs", fill: "#4f7942"},
{source: "13: development programs", target: "13: possible future legal actions", fill: "#4f7942"},
{source: "13: possible future legal actions", target: "13: marketing organization", fill: "#4f7942"},
{source: "13: marketing organization", target: "13: OcuGene ", fill: "#4f7942"},
{source: "13: OcuGene ", target: "13: promotional activities", fill: "#4f7942"},
{source: "13: promotional activities", target: "13: termination", fill: "#4f7942"},
{source: "13: termination", target: "13: existing collaboration", fill: "#4f7942"},
{source: "13: existing collaboration", target: "13: arrangements", fill: "#4f7942"},
{source: "13: arrangements", target: "13: products ourselves", fill: "#4f7942"},
{source: "13: products ourselves", target: "13: cost involved", fill: "#4f7942"},
{source: "13: cost involved", target: "13: regulatory approvals", fill: "#4f7942"},
{source: "13: regulatory approvals", target: "13: filing prosecuting defending", fill: "#4f7942"},
{source: "13: filing prosecuting defending", target: "13: enforcing patent", fill: "#4f7942"},
{source: "13: enforcing patent", target: "13: intellectual property rights", fill: "#4f7942"},
{source: "13: intellectual property rights", target: "13: competing technological", fill: "#4f7942"},
{source: "13: competing technological", target: "13: market developments", fill: "#4f7942"},
{source: "13: market developments", target: "13: additional capital equipment", fill: "#4f7942"},
{source: "13: difficult", target: "19: expensive timeconsuming", fill: "#00416a"},
{source: "19: expensive timeconsuming", target: "19: difficult", fill: "#00416a"},
{source: "19: difficult", target: "19: unclear whether", fill: "#00416a"},
{source: "19: unclear whether", target: "19: such clinical trials", fill: "#00416a"},
{source: "19: such clinical trials", target: "19: commenced two", fill: "#00416a"},
{source: "19: commenced two", target: "19: product candidate", fill: "#00416a"},
{source: "19: expensive timeconsuming", target: "81: Competition ", fill: "#afeeee"},
{source: "81: Competition ", target: "81: biotechnology", fill: "#afeeee"},
{source: "81: biotechnology", target: "81: highly intense", fill: "#afeeee"},
{source: "81: highly intense", target: "81: personnel necessary", fill: "#afeeee"},
{source: "81: personnel necessary", target: "81: development", fill: "#afeeee"},
{source: "81: Competition ", target: "START_HERE", fill: "#afeeee"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Humanitarian</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Protest demonstrations</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Globe_Sessions">The Globe Sessions</a></td>
      <td>The Globe Sessions is the third studio album by American singer-songwriter Sheryl Crow, released on September 21, 1998, in the United Kingdom and September 29, 1998, in the United States, then re-released in 1999. It was nominated for Album of the Year, Best Rock Album and Best Engineered Non-Classical Album at the 1999 Grammys, winning the latter two awards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>INSITE VISION INC      Item 1A Risk Factors       Our <font color="blue"><font color="blue">current cash</font> will only fund</font> our business <font color="blue">until <font color="blue">approximately</font></font> the end of     June 2006</td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> funding</font>, either through equity or debt     <font color="blue">financings</font> or <font color="blue">partnering <font color="blue"><font color="blue">arrangement</font>s</font></font>, that could be <font color="blue">further dilutive</font> to our     <font color="blue">stockholders</font> and <font color="blue">could negatively affect us</font> and our stock price       Our <font color="blue">in<font color="blue">dependent</font> auditors</font> included an <font color="blue"><font color="blue">explanatory</font> paragraph</font> in their audit     report related to our <font color="blue">consolidated financial statements</font> for the <font color="blue">fiscal year</font>     ended <font color="blue">December </font>31, 2005 referring to our recurring operating losses and a     substantial <font color="blue">doubt about</font> our ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>We  only  expect our <font color="blue">current cash</font> (including cash received for warrant     exercises after <font color="blue">December </font>31, 2005 and from the <font color="blue">January </font>2006 closing of our     <font color="blue">Senior Secured Notes </font>financing) to <font color="blue">enable us</font> to continue our <font color="blue"><font color="blue">operations</font> as</font>     currently planned <font color="blue">until <font color="blue">approximately</font></font> the end of June 2006</td>
    </tr>
    <tr>
      <td>At that point,     or earlier if <font color="blue">circumstances</font> change from our <font color="blue">current <font color="blue">expectations</font></font>, we will     require <font color="blue"><font color="blue">additional</font> funding</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue"><font color="blue">additional</font> funding</font>     will be <font color="blue">available on</font> a <font color="blue">timely basis</font>, or <font color="blue">on reasonable terms</font>, or at all</td>
    </tr>
    <tr>
      <td>The     terms of any <font color="blue">securities issued</font> to <font color="blue">future investors may</font> be superior to the     rights of our then current <font color="blue">stockholders</font> and could result in substantial     dilution and <font color="blue">could <font color="blue">adversely affect</font></font> the <font color="blue">market price</font> for our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise funds through</font> the issuance of debt securities, such debt will     likely be <font color="blue">secured by</font> a <font color="blue">security interest</font> or pledge of all of our assets,     will require us to make principal and <font color="blue">interest payments</font> in cash, securities     or a combination thereof, <font color="blue">would likely</font> include the issuance of warrants, and     may subject us to <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td>If we do not obtain <font color="blue">such <font color="blue">additional</font></font>     financing  when required, we <font color="blue">would likely</font> have to <font color="blue">cease <font color="blue">operations</font></font> and     liquidate  our  assets</td>
    </tr>
    <tr>
      <td>In addition, the existence of the <font color="blue">explanatory</font>     paragraph in the audit report may in and of <font color="blue">itself harm</font> our <font color="blue">stock price as</font>     <font color="blue">certain investors may</font> be restricted or <font color="blue">precluded from investing</font> in companies     that have received this notice in an audit report</td>
    </tr>
    <tr>
      <td>Further, the factors     leading  to the <font color="blue"><font color="blue">explanatory</font> paragraph</font> in the audit report may harm our     ability to obtain <font color="blue"><font color="blue">additional</font> funding</font> and could make the terms of any such     funding, if available, less favorable <font color="blue">than might otherwise</font> be the case</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________       In  addition,  we  expect  to  <font color="blue"><font color="blue">enter into</font> partnering</font> and <font color="blue">collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font> in the future as part of our business plan, <font color="blue">regardless</font> of     whether we require <font color="blue"><font color="blue">additional</font> funding</font> to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue"><font color="blue">arrangement</font>s</font> could include the <font color="blue">exclusive licensing</font> or sale of <font color="blue">certain assets</font>     or  the  issuance of securities, which may <font color="blue">adversely affect</font> our future     <font color="blue">financial performance</font> and the <font color="blue">market price</font> of our <font color="blue">Common Stock</font> and we cannot     assure you that such <font color="blue"><font color="blue">arrangement</font>s</font> will be <font color="blue">beneficial</font> to us</td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font>     to <font color="blue">precisely predict</font> our <font color="blue">future capital <font color="blue">requirements</font> as such <font color="blue">requirements</font></font>     <font color="blue">depend upon</font> many factors, including:       ·     the progress and results of our preclinical and <font color="blue">clinical testing</font>, especially     results of our ongoing Phase 3 <font color="blue">clinical trials</font> for our AzaSite product     candidate;       ·     our ability to <font color="blue">establish <font color="blue">additional</font> corporate partnerships</font> to develop,     <font color="blue">manufacture</font> and market our <font color="blue"><font color="blue">potential product</font>s</font>;       ·     the progress of our research and <font color="blue"><font color="blue">development</font> programs</font>;       ·     the outcome of existing or <font color="blue">possible future legal actions</font>;       ·     the cost of maintaining or expanding a <font color="blue">marketing organization</font> for <font color="blue">OcuGene     </font>and the related <font color="blue">promotional <font color="blue">activities</font></font>;       ·     changes in, or <font color="blue">termination</font> of, our <font color="blue">existing <font color="blue">collaboration</font></font> or licensing     <font color="blue"><font color="blue">arrangement</font>s</font>;       ·     whether we <font color="blue">manufacture</font> and market any of our other <font color="blue">products ourselves</font>;       ·     the time and <font color="blue">cost involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font>;       ·     the cost of filing, prosecuting, defending and <font color="blue">enforcing patent</font> claims and     other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>;       ·     <font color="blue">competing technological</font> and <font color="blue">market <font color="blue">development</font>s</font>; and       ·     the purchase of <font color="blue"><font color="blue">additional</font> capital equipment</font></td>
    </tr>
    <tr>
      <td>If  we  do  not receive <font color="blue"><font color="blue">additional</font> funding</font> when needed to continue our     <font color="blue">operations</font> we will likely <font color="blue">cease <font color="blue">operations</font></font> and liquidate our assets, which     are <font color="blue">secured by</font> notes payable to the holders of our <font color="blue">December </font>2005/<font color="blue">January </font>    2006 <font color="blue">Senior Secured Notes </font>and our <font color="blue"><font color="blue">chief executive</font> officer</font>        In the event that we are unable to secure <font color="blue"><font color="blue">additional</font> funding</font> when required     to  continue our <font color="blue">operations</font>, we will likely be forced to wind down our     <font color="blue">operations</font>, either through <font color="blue">liquidation</font>, voluntary or <font color="blue">involuntary</font> <font color="blue">bankruptcy</font>     or a sale of our assets</td>
    </tr>
    <tr>
      <td>As of <font color="blue">January </font>31, 2006, we had <font color="blue">outstanding secured</font>     <font color="blue">indebtedness under</font> our <font color="blue">December </font>2005/<font color="blue">January </font>2006 <font color="blue">Senior Secured Notes </font>(the     “Senior Secured Notes”) and a note issued to our <font color="blue"><font color="blue">chief executive</font> officer</font> in     an <font color="blue">aggregate principal amount</font> of dlra6cmam531cmam000, which is <font color="blue">secured by</font> a lien on     all of our assets including our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>In the event that we     wind down <font color="blue">operations</font>, whether <font color="blue">voluntarily</font> or in<font color="blue">voluntarily</font>, while these     secured notes are outstanding, this <font color="blue">security interest</font> enables the holders of     our <font color="blue">Senior Secured Notes </font>to control the <font color="blue">disposition</font> of these assets</td>
    </tr>
    <tr>
      <td>If we     are unable to repay the <font color="blue">amounts due under</font> the secured notes when due, the     holders of such notes could cause us to <font color="blue">enter into</font> <font color="blue">involuntary</font> <font color="blue">liquidation</font>     <font color="blue">proceedings</font>  in the event we <font color="blue">default on</font> our <font color="blue">obligations</font> and could take     possession of our assets</td>
    </tr>
    <tr>
      <td>If we wind down our <font color="blue">operations</font> for any reason, it     is likely that our <font color="blue">stockholders</font> will lose their <font color="blue">entire investment</font> in us</td>
    </tr>
    <tr>
      <td>Clinical trials are very expensive, time-consuming and <font color="blue">difficult</font> to design     and implement and it is <font color="blue">unclear whether</font> the results of <font color="blue">such <font color="blue">clinical trials</font></font>     will be favorable        We <font color="blue">commenced two</font> Phase 3 trials of our AzaSite <font color="blue">product candidate</font> in the     third  quarter of 2004</td>
    </tr>
    <tr>
      <td>In October 2005 we announced the <font color="blue">completion</font> of     <font color="blue">enrollment</font> in one of the two Phase 3 trials and in <font color="blue">December </font>2005 announced     <font color="blue">preliminary</font> results of that <font color="blue">first trial</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">January </font>2006 we announced the     <font color="blue">completion</font> of <font color="blue">enrollment</font> in the second Phase 3 trial and in March 2006     announced the results of that trial</td>
    </tr>
    <tr>
      <td>We expect our <font color="blue">current cash</font> will only be     sufficient to <font color="blue">enable us</font> to continue our <font color="blue"><font color="blue">operations</font> as</font> currently planned     until  <font color="blue">approximately</font> the end of June 2006</td>
    </tr>
    <tr>
      <td>Accordingly, we may require     <font color="blue">additional</font>  funds  to prepare the related clinical reports, obtain the     <font color="blue">necessary</font> FDA approvals and market the product</td>
    </tr>
    <tr>
      <td>Any delay or failure in the     filing of our <font color="blue">NDA for AzaSite </font>or in the FDA <font color="blue">approval process will likely</font>     require us to obtain <font color="blue">even further funding</font> and such delay or <font color="blue">failure could</font>     make it much more <font color="blue">difficult</font> or expensive for us to obtain funding</td>
    </tr>
    <tr>
      <td><font color="blue">Human     </font><font color="blue">clinical trials</font> for our <font color="blue">product candidate</font>s are very expensive and <font color="blue">difficult</font>     to  design and implement, in part because they are subject to rigorous     <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial process</font> is also time-consuming</td>
    </tr>
    <tr>
      <td>We estimate that <font color="blue">clinical trials</font> of our other <font color="blue">product candidate</font>s will take     <font color="blue">at least several years</font> to complete <font color="blue">once initiated</font></td>
    </tr>
    <tr>
      <td>Furthermore, we could     <font color="blue">encounter problems</font> that cause us to abandon or repeat <font color="blue">clinical trials</font>,     further  delaying  or  preventing  the  <font color="blue">completion</font> of such trials</td>
    </tr>
    <tr>
      <td>The     <font color="blue">commencement</font> and <font color="blue">completion</font> of <font color="blue">clinical trials</font> may be <font color="blue">delayed by several</font>     factors, including:               15       _________________________________________________________________       ·     <font color="blue">unforeseen safety issues</font>;       ·     de<font color="blue">termination</font> of <font color="blue">dosing issues</font>;       ·     lack of <font color="blue">effective</font>ness during <font color="blue">clinical trials</font>;       ·     <font color="blue">slower than</font> expected rates of <font color="blue">patient recruitment</font>;       ·     <font color="blue">inability</font> to <font color="blue">monitor patients <font color="blue">adequately</font> during</font> or after treatment; and       ·     <font color="blue">inability</font> or <font color="blue">unwillingness</font> of <font color="blue">medical investigators</font> to follow our clinical     protocols</td>
    </tr>
    <tr>
      <td>In addition, we or the FDA may suspend our <font color="blue">clinical trials</font> at any time if it     appears that we are <font color="blue">exposing participants</font> to unacceptable <font color="blue">health risks</font> or if     the  FDA <font color="blue">finds deficiencies</font> in our <font color="blue">submissions</font> or the conduct of these     trials</td>
    </tr>
    <tr>
      <td>The results of our <font color="blue">clinical trials</font> may not support our <font color="blue">product candidate</font>     claims        Even if our <font color="blue">clinical trials</font> are completed as planned, we cannot be certain     that  their results <font color="blue">will support</font> our <font color="blue">product candidate</font> claims</td>
    </tr>
    <tr>
      <td>Even if     pre-<font color="blue">clinical testing</font> and early <font color="blue">clinical trials</font> for a <font color="blue">product candidate</font> are     successful,  this  does  not ensure that later <font color="blue">clinical trials</font> will be     successful, and we cannot be sure that the results of later <font color="blue">clinical trials</font>     <font color="blue">will replicate</font> the results of prior <font color="blue">clinical trials</font> and pre-<font color="blue">clinical testing</font>     or meet our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial process</font> may fail to <font color="blue">demonstrate</font>     that our <font color="blue">product candidate</font>s are safe for humans or <font color="blue">effective</font> for indicated     uses</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">clinical trials</font> involve relatively small patient     <font color="blue">populations</font></td>
    </tr>
    <tr>
      <td>Because of the small sample size, the results of these clinical     <font color="blue">trials may</font> not be <font color="blue">indicative</font> of future results</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such failure would</font>     likely cause us to abandon the <font color="blue">product candidate</font> and <font color="blue">may delay <font color="blue">development</font></font>     of other <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>Any delay in, or <font color="blue">termination</font> of, our clinical     <font color="blue">trials will delay</font> or preclude the filing of our NDAs with the FDA and,     ultimately, our ability to <font color="blue">commercialize</font> our <font color="blue">product candidate</font>s and generate     product  revenues</td>
    </tr>
    <tr>
      <td>For example, if the FDA determines that our current     AzaSite  Phase  3 trials did not produce <font color="blue">sufficient evidence</font> to obtain     approval for the <font color="blue">commercialization</font> of <font color="blue">AzaSite or the FDA </font>refuses to grant     our <font color="blue">AzaSite NDA </font>for any other reason, our business would be <font color="blue">significant</font>ly     <font color="blue">harmed as</font> we have devoted a <font color="blue">significant</font> portion of our resources to this     <font color="blue">product candidate</font>, at the expense of our other <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We may require <font color="blue">additional</font> licenses or be subject to expensive and uncertain     <font color="blue">patent <font color="blue">litigation</font></font> in order to sell <font color="blue">AzaSite <font color="blue">in the US </font></font>and/or Europe; We are     aware that Pfizer has recently received patents in the <font color="blue">US and Europe </font>which     cover the use of <font color="blue">azithromycin</font> in a <font color="blue">topical <font color="blue">formulation</font></font> to <font color="blue">treat bacterial</font>     <font color="blue">infections</font> in the eye        A number of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font> and research and     <font color="blue">academic institutions</font> have developed <font color="blue">technologies</font>, <font color="blue">filed patent</font> <font color="blue">applications</font>     or received <font color="blue">patents on various <font color="blue">technologies</font></font> that may be related to our     business</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">technologies</font>, <font color="blue">applications</font> or patents may conflict     with  our  <font color="blue">technologies</font>  or  patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">conflicts could</font>     invalidate our issued patents, limit the scope of the patents, if any, we     may be able to obtain, result in the denial of our patent <font color="blue">applications</font> or     block our rights to exploit our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, if the USPTO or     foreign  patent  agencies  have issued or issue patents that cover our     <font color="blue">activities</font> to other companies, we may not be able to obtain licenses to     these <font color="blue">patents at</font> all, or at a <font color="blue">reasonable cost</font>, or be able to develop or     obtain alternative <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we do not obtain <font color="blue">such licenses</font>, we could     <font color="blue">encounter delays</font> in or be <font color="blue">precluded altogether from introducing products</font> to     the market</td>
    </tr>
    <tr>
      <td>We are aware that Pfizer has <font color="blue">been issued</font> US Patent Nodtta 6cmam681cmam411 by the     <font color="blue">USPTO and the European Patent Office </font>has granted its European <font color="blue">counterpart</font> EP     0925789,  both  of  which  cover  the use of <font color="blue">azithromycin</font> in a topical     <font color="blue">formulation</font> to treat ophthalmic <font color="blue">infections</font></td>
    </tr>
    <tr>
      <td>We may require a <font color="blue">license under</font>     these patents to develop or sell AzaSite for ophthalmic <font color="blue">indications</font> in the     US and/or Europe, which may not be <font color="blue">available on</font> reasonable commercial     terms, if at all</td>
    </tr>
    <tr>
      <td>If we are unable to obtain a license to these patents,     Pfizer  brings  suit to enforce them, these patents are held valid and     enforceable and our <font color="blue">technology</font> is deemed to infringe these patents, <font color="blue">Pfizer     </font>would be entitled to damages and we could be <font color="blue">prevented from selling</font> AzaSite     in Europe and/or the US       We may need to litigate in order to <font color="blue">defend against</font> claims of <font color="blue"><font color="blue">infringement</font> by</font>     Pfizer  or others, to enforce patents issued to us or to <font color="blue">protect trade</font>     secrets or know-how owned or <font color="blue">licensed by us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>could result in     substantial  cost to and diversion of effort by us, which may harm our     business, prospects, financial condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>costs can be <font color="blue"><font color="blue">particularly</font> harmful</font> to <font color="blue">emerging companies such as ours without</font>     <font color="blue">significant</font> existing revenue streams or other <font color="blue">cash resources</font></td>
    </tr>
    <tr>
      <td>We have also     agreed to indemnify our <font color="blue">licensees against <font color="blue">infringement</font></font> claims by third     parties  related  to  our <font color="blue">technology</font>, <font color="blue">which could</font> result in <font color="blue">additional</font>     <font color="blue"><font color="blue">litigation</font> costs</font> and <font color="blue">liability</font> for us</td>
    </tr>
    <tr>
      <td>In addition, our efforts to protect     or  defend  our  <font color="blue">proprietary</font>  <font color="blue">rights may</font> not be successful or, even if     successful, may result in substantial cost to us, thereby utilizing our     limited  resources  for  purposes  other  <font color="blue">than product <font color="blue">development</font></font> and     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________       If our products, methods, processes and other <font color="blue">technologies</font> infringe the     <font color="blue">proprietary</font> rights of other parties, we <font color="blue">could incur</font> substantial costs and we     may have to:       ·     obtain licenses, which may not be <font color="blue">available on</font> <font color="blue"><font color="blue">commercially</font> reasonable</font>     terms, if at all;       ·     redesign our products or processes to <font color="blue">avoid <font color="blue">infringement</font></font>;       ·     stop using the subject matter claimed in the patents held by others, which     <font color="blue">could preclude us from commercializing</font> our products;       ·     pay damages; or       ·     <font color="blue">defend <font color="blue">litigation</font></font> or <font color="blue">administrative</font> <font color="blue">proceedings</font> which may be <font color="blue">costly whether</font>     we win or lose, and <font color="blue">which could</font> result in a substantial diversion of our     valuable <font color="blue"><font color="blue">management</font> resources</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends upon</font> our <font color="blue">proprietary</font> rights, and we may not be able to     protect, enforce or secure our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> <font color="blue">adequately</font>        Our  <font color="blue">future success will depend</font> in large part on our ability to obtain     patents, <font color="blue">protect trade</font> secrets, obtain and maintain rights to <font color="blue">technology</font>     developed by others, and operate <font color="blue">without infringing upon</font> the <font color="blue">proprietary</font>     rights  of  others</td>
    </tr>
    <tr>
      <td>A  substantial  number of patents in the field of     <font color="blue">ophthalmology</font> and genetics have <font color="blue">been issued</font> to <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font>     and bio<font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue"><font color="blue">competitors</font> may</font> have <font color="blue">filed patent</font>     <font color="blue">applications</font>, may have <font color="blue">been issued</font> patents or may obtain <font color="blue">additional</font> patents     and <font color="blue">proprietary</font> rights relating to products or <font color="blue">processes <font color="blue">competitive</font> with</font>     ours</td>
    </tr>
    <tr>
      <td>Our patent <font color="blue">applications</font> may not be approved</td>
    </tr>
    <tr>
      <td>We may not be able to     develop <font color="blue">additional</font> <font color="blue">proprietary</font> products that are patentable</td>
    </tr>
    <tr>
      <td>Even if we     receive <font color="blue">patent issuances</font>, those <font color="blue">issued patents may</font> not be able to <font color="blue">provide us</font>     <font color="blue">with adequate protection</font> for our <font color="blue">inventions</font> or may be <font color="blue">challenged by others</font></td>
    </tr>
    <tr>
      <td>Furthermore, the patents of others may impair our ability to <font color="blue">commercialize</font>     our  products</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of firms in the <font color="blue">pharmaceutical</font> and     <font color="blue">genetic industries generally</font> are highly uncertain, involve complex legal and     factual questions, and have <font color="blue">recently been</font> the subject of much <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">The USPTO </font>and the courts have not developed, formulated, or presented a     <font color="blue">consistent policy</font> regarding the breadth of claims allowed or the degree of     protection afforded under <font color="blue">pharmaceutical</font> and <font color="blue">genetic patents</font></td>
    </tr>
    <tr>
      <td>Despite our     efforts to protect our <font color="blue">proprietary</font> rights, others may <font color="blue">in<font color="blue">dependent</font>ly</font> develop     similar products, duplicate any of our products or <font color="blue">design around</font> any of our     patents</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font> from which we have licensed or otherwise     obtained <font color="blue">technology</font> may attempt to terminate or scale back our rights</td>
    </tr>
    <tr>
      <td>We also <font color="blue">depend upon</font> unpatented trade secrets to maintain our <font color="blue">competitive</font>     position</td>
    </tr>
    <tr>
      <td>Others  may  <font color="blue">in<font color="blue">dependent</font>ly</font> develop <font color="blue"><font color="blue">substantially</font> equivalent</font>     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our trade     secrets</td>
    </tr>
    <tr>
      <td>Our <font color="blue">trade secrets may also</font> be disclosed, and we may not be able to     protect our rights to unpatented trade secrets <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>To the extent     that  we or our <font color="blue">consultants</font> or research <font color="blue">collaborators</font> use <font color="blue">intellectual</font>     property  owned by others, disputes also may arise as to the rights in     related or resulting know-how and <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current financial</font> situation may impede our ability to protect or enforce     <font color="blue">adequately</font>  our  <font color="blue"><font color="blue">legal rights under</font> <font color="blue">agreement</font>s</font> and to our <font color="blue">intellectual</font>     property        We  expect our <font color="blue">current cash</font> to <font color="blue">enable us</font> to continue our <font color="blue"><font color="blue">operations</font> as</font>     currently planned only <font color="blue">until <font color="blue">approximately</font></font> the end of June 2006</td>
    </tr>
    <tr>
      <td>Our limited     financial  resources  make  it  more  <font color="blue">difficult</font>  for us to enforce our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, through the filing or maintenance of patents,     taking <font color="blue">legal action against</font> those that <font color="blue">may infringe on</font> our <font color="blue">proprietary</font>     rights, defending <font color="blue">infringement</font> claims <font color="blue">against us</font>, or otherwise</td>
    </tr>
    <tr>
      <td>Our current     financial situation may impede our ability to enforce our <font color="blue">legal rights under</font>     <font color="blue">various <font color="blue">agreement</font>s</font> we are currently a party to or may become a party to due     to our <font color="blue">inability</font> to incur the <font color="blue">costs associated with such enforcement</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to <font color="blue">adequately</font> protect our legal and <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>     may make us more vulnerable to <font color="blue">infringement</font> and <font color="blue">could materially harm</font> our     business</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________       We are <font color="blue"><font color="blue">dependent</font> upon <font color="blue">key employees</font></font> and we may not be able to retain or     attract <font color="blue">key employees</font>, and our ability to attract and retain <font color="blue">key employees</font>     is likely to be <font color="blue">harmed by</font> our <font color="blue">current financial</font> situation        We are <font color="blue">highly <font color="blue">dependent</font> on</font> Dr</td>
    </tr>
    <tr>
      <td>Chandrasekaran, who is our <font color="blue">chief executive</font>     officer, president and chief financial officer, and Dr</td>
    </tr>
    <tr>
      <td>Lyle Bowman, our     vice president, <font color="blue">development</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">services from either</font>     of these <font color="blue">key personnel</font> might <font color="blue">significant</font>ly delay or prevent the <font color="blue">achievement</font>     of planned <font color="blue"><font color="blue">development</font> objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Chandrasekaran </font>under which we are the <font color="blue">sole beneficiary</font>,     however in the event of the death of Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Chandrasekaran </font><font color="blue">such policy would</font> be     unlikely to <font color="blue">fully compensate us</font> for the hardship and expense in finding a     <font color="blue">successor such</font> a loss would cause us</td>
    </tr>
    <tr>
      <td>We do not carry a <font color="blue">life insurance</font>     policy on Dr</td>
    </tr>
    <tr>
      <td>Furthermore, a critical factor to our success will be     recruiting  and retaining qualified personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for skilled     individuals in the bio<font color="blue">technology</font> business is <font color="blue">highly intense</font>, and we may not     be  able to continue to attract and retain personnel <font color="blue">necessary</font> for the     <font color="blue">development</font>  of  our  business</td>
    </tr>
    <tr>
      <td>Our ability to attract and retain such     <font color="blue">individuals may</font> be <font color="blue">reduced by</font> our recent and current <font color="blue">difficult</font> financial     situation and our <font color="blue">past reductions</font> in force</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel</font> or the     failure to recruit <font color="blue">additional</font> personnel or to develop needed <font color="blue">expertise would</font>     harm our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">third parties</font></font> to develop, market and sell our products; we may     not be able to continue or <font color="blue">enter into</font> <font color="blue">third party</font> <font color="blue"><font color="blue">arrangement</font>s</font>, and these     <font color="blue">third parties</font>’ efforts may not be successful        We do not plan <font color="blue">on <font color="blue">establishing</font></font> an internal, dedicated <font color="blue">sales force</font> or a     <font color="blue">marketing organization</font> for our <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on third</font>     parties  for  clinical  testing  and certain other product <font color="blue">development</font>     <font color="blue">activities</font> especially in the area of our <font color="blue">glaucoma programs</font></td>
    </tr>
    <tr>
      <td>We are currently     pursuing a licensing or <font color="blue">collaborative</font> <font color="blue">agreement</font> for the sale and marketing     of our AzaSite <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font> that we will be     successful in <font color="blue"><font color="blue">entering into</font> such</font> an <font color="blue">agreement</font> or that a <font color="blue">partner would</font> be     successful in their efforts, either of <font color="blue">which could</font> <font color="blue">significant</font>ly harm our     business</td>
    </tr>
    <tr>
      <td>In order to pursue our anti-inflammatory and <font color="blue">glaucoma programs</font>,     ISV-205, we <font color="blue">must <font color="blue">enter into</font></font> a <font color="blue">third party</font> <font color="blue">collaboration</font> <font color="blue">agreement</font> for the     <font color="blue">development</font>, marketing and <font color="blue">sale thereof</font> or develop, market and sell the     <font color="blue">product ourselves</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be successful in     finding  a  corporate  partner  for  our  ISV-205 programs or that any     <font color="blue"><font color="blue">collaboration</font> will</font> be successful, either of <font color="blue">which could</font> <font color="blue">significant</font>ly harm     our business</td>
    </tr>
    <tr>
      <td>In addition, we have no experience in marketing and selling     products and we <font color="blue">cannot assure</font> you that we would be successful in marketing     ISV-205  ourselves</td>
    </tr>
    <tr>
      <td>If we are to develop and <font color="blue">commercialize</font> our product     <font color="blue">candidates</font> successfully, including ISV-205, we will be required to enter     into <font color="blue"><font color="blue">arrangement</font>s</font> with one or more <font color="blue">third parties</font> that will:       ·     provide <font color="blue">for Phase </font>2 and/or Phase 3 <font color="blue">clinical testing</font>;       ·     obtain or <font color="blue">assist us</font> in other <font color="blue">activities</font> associated with obtaining <font color="blue">regulatory</font>     approvals for our <font color="blue">product candidate</font>s; and       ·     market and sell our products, if they are approved</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2003, we completed the sale of our <font color="blue">drug candidate</font> ISV-403 for     the treatment of ocular <font color="blue">infections</font> to Bausch &amp; Lomb Incorporated</td>
    </tr>
    <tr>
      <td>Bausch &amp;     Lomb  has assumed all future ISV-403 <font color="blue">development</font> and <font color="blue">commercialization</font>     expenses  and  is responsible for all <font color="blue">development</font> <font color="blue">activities</font>, with our     assistance, as appropriate</td>
    </tr>
    <tr>
      <td>The Bausch &amp; Lomb Purchase Agreement and License     Agreement grants Bausch &amp; Lomb rights to develop and market ISV-403, subject     to  payment  of royalties, in all <font color="blue">geographies except</font> Japan (which were     retained by SSP, in <font color="blue">connection</font> with a separate license <font color="blue">agreement</font> between us     and SSP), <font color="blue">with such rights</font> being <font color="blue">shared with</font> SSP in Asia (except Japan) and     exclusive elsewhere</td>
    </tr>
    <tr>
      <td>This sale resulted in the <font color="blue">termination</font> of the <font color="blue">August     </font>2002  license  <font color="blue">agreement</font> we <font color="blue"><font color="blue">entered into</font> with</font> Bausch &amp; Lomb related to     ISV-403</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate <font color="blue">royalties from</font></font> this <font color="blue">agreement</font> will be     <font color="blue">dependent</font>  upon Bausch &amp; Lomb’s ability to complete the <font color="blue">development</font> of     ISV-403, obtain <font color="blue">regulatory</font> approval for the product and <font color="blue">successfully market</font>     it</td>
    </tr>
    <tr>
      <td>In addition, under the Bausch &amp; Lomb Purchase Agreement, we also have     certain potential indemnification <font color="blue">obligations</font> to Bausch &amp; Lomb in <font color="blue">connection</font>     with  the asset sale which, if triggered, could <font color="blue">significant</font>ly harm our     business and our financial position</td>
    </tr>
    <tr>
      <td>Our marketing and <font color="blue">sales efforts</font> related to our OcuGene <font color="blue"><font color="blue">glaucoma genetic</font> test</font>     have  been <font color="blue">significant</font>ly curtailed</td>
    </tr>
    <tr>
      <td>Any future <font color="blue">activities</font> would mainly     <font color="blue">pursued using external resources</font> that included:       ·     a network of <font color="blue">key ophthalmic clinicians</font>; and       ·     other <font color="blue">resources <font color="blue">with ophthalmic</font> expertise</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       We may not be able to <font color="blue">enter into</font> or maintain <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font>     <font color="blue">with ophthalmic</font> or <font color="blue"><font color="blue">diagnostic</font> industry</font> experience on acceptable terms or at     all</td>
    </tr>
    <tr>
      <td>If we are not successful in concluding such <font color="blue"><font color="blue">arrangement</font>s</font> on acceptable     terms, or at all, we may be required to establish our own <font color="blue">sales force</font> and     expand our <font color="blue">marketing organization</font> <font color="blue">significant</font>ly, despite the fact that we     have no experience in sales, marketing or <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Even if we do enter     into <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> these <font color="blue"><font color="blue">relationship</font>s</font> can be terminated     <font color="blue">forcing us</font> to <font color="blue">seek alternatives</font></td>
    </tr>
    <tr>
      <td>We may not be able to build a marketing     staff  or  sales  force and our sales and <font color="blue">marketing efforts may</font> not be     cost-<font color="blue">effective</font> or successful</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">currently <font color="blue">contract with</font></font> a <font color="blue">third party</font> to assemble the sample     <font color="blue"><font color="blue">collection</font> kits used</font> in our OcuGene <font color="blue"><font color="blue">glaucoma genetic</font> test</font></td>
    </tr>
    <tr>
      <td>If our assembler     should encounter <font color="blue">significant</font> delays or we have <font color="blue">difficult</font>y maintaining our     <font color="blue">existing <font color="blue">relationship</font></font>, or in <font color="blue">establishing</font> a new one, our sales of this     <font color="blue">product could</font> be <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Our strategy for research, <font color="blue">development</font> and <font color="blue">commercialization</font> of our products     requires us to <font color="blue">enter into</font> various <font color="blue"><font color="blue">arrangement</font>s</font> with corporate and academic     <font color="blue">collaborators</font>,  <font color="blue">licensors</font>,  licensees  and others; furthermore, we are     <font color="blue">dependent</font> on the <font color="blue">diligent efforts</font> and <font color="blue">subsequent success</font> of these outside     parties in performing their <font color="blue">responsibilities</font>        Because of our reliance on <font color="blue">third parties</font> for the <font color="blue">development</font>, marketing and     sale of our products, any revenues that we receive will be <font color="blue">dependent</font> on the     efforts of these <font color="blue">third parties</font>, such as our corporate <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">partners may terminate</font> their <font color="blue"><font color="blue">relationship</font>s</font> with us and may not <font color="blue">diligently</font> or     <font color="blue">successfully market</font> our products</td>
    </tr>
    <tr>
      <td>In addition, marketing <font color="blue">consultants</font> and     <font color="blue">contract sales organizations</font>, we may use in the future for OcuGene and     potential future products such as AzaSite, <font color="blue">may market products</font> that compete     with our products and we <font color="blue">must rely on</font> their efforts and ability to market     and  sell  our  products  <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We may not be able to conclude     <font color="blue"><font color="blue">arrangement</font>s</font> with other companies to support the <font color="blue">commercialization</font> of our     <font color="blue">products on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">current financial</font>     <font color="blue">condition may</font> make us a <font color="blue">less attractive partner</font> to potential <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborators</font> may take the position that they are free to     compete  using  our  <font color="blue">technology</font>  <font color="blue">without compensating</font> or <font color="blue">entering into</font>     <font color="blue">agreement</font>s with us</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">collaborators</font> may pursue alternative     <font color="blue">technologies</font> or develop <font color="blue">alternative products either on</font> their own or in     <font color="blue">collaboration</font>  with  others, including our <font color="blue">competitors</font>, as a means for     developing  <font color="blue">treatments</font> for the diseases or <font color="blue">disorders targeted by</font> these     <font color="blue">collaborative</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>and <font color="blue">patients may</font> not accept and use our products        Even if the FDA approves our <font color="blue">product candidate</font>s, physicians and <font color="blue">patients may</font>     not accept and use them</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>and use of our product will <font color="blue">depend upon</font>     a number of factors including:       ·     <font color="blue">perceptions</font> by members of the <font color="blue">health care community</font>, including physicians,     about the safety and <font color="blue">effective</font>ness of our drugs;       ·     cost-<font color="blue">effective</font>ness of our <font color="blue">product relative</font> to <font color="blue">competing products</font>;       ·     the perceived benefits of <font color="blue">competing products</font> or <font color="blue">treatments</font>;       ·     <font color="blue">availability</font> of <font color="blue">reimbursement</font> for our <font color="blue">products from <font color="blue">government</font></font> or other     <font color="blue">healthcare payers</font>; and       ·     <font color="blue">effective</font>ness of marketing and <font color="blue">distribution</font> efforts by us and our licensees     and <font color="blue">distributors</font>, if any</td>
    </tr>
    <tr>
      <td>Because we expect sales of our current <font color="blue">product candidate</font>s, if approved, to     <font color="blue">generate <font color="blue">substantially</font></font> all of our <font color="blue">product revenues</font> for the foreseeable     future, the failure of any of these drugs, <font color="blue">particularly</font> AzaSite, to find     market <font color="blue">acceptance</font> would harm our business and could require us to seek     <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td><font color="blue">Questions </font><font color="blue">concerning</font> our financial <font color="blue">condition may</font> cause customers and current     and <font color="blue">potential partners</font> to reduce or not conduct business with us        Our recent and on-going financial <font color="blue">difficult</font>ies, and concerns regarding our     ability to continue <font color="blue">operations</font>, even if we are able to raise <font color="blue">additional</font>     funding, may cause current and <font color="blue">potential customers</font> and partners to decide     not to conduct business with us, to reduce or terminate the business they     <font color="blue">currently conduct with us</font>, or to conduct business <font color="blue">with us on terms</font> that are     less favorable than those <font color="blue">customarily offered by them</font></td>
    </tr>
    <tr>
      <td>In such event, our     sales  would  likely  decrease,  our <font color="blue">costs could increase</font>, our product     <font color="blue">development</font> and <font color="blue">commercialization</font> efforts would suffer and our business will     be <font color="blue">significant</font>ly harmed</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________       It is <font color="blue">difficult</font> to evaluate our business because we are in an <font color="blue">early stage</font> of     <font color="blue">development</font> and our <font color="blue">technology</font> is untested        We are in an <font color="blue">early stage</font> of developing our business</td>
    </tr>
    <tr>
      <td>We have only received     an in<font color="blue">significant</font> amount of <font color="blue">royalties from</font> the sale of one of our products,     an over-the-counter dry eye treatment, and in 2002 we began to receive a     small amount of <font color="blue">revenues from</font> the sale of our OcuGene <font color="blue"><font color="blue">glaucoma genetic</font> test</font></td>
    </tr>
    <tr>
      <td>Before <font color="blue">regulatory</font> authorities grant us marketing approval for <font color="blue">additional</font>     products, we need to conduct <font color="blue">significant</font> <font color="blue">additional</font> research and <font color="blue">development</font>     and preclinical and <font color="blue">clinical testing</font>, including <font color="blue">with respect</font> to our leading     <font color="blue">product candidate</font> AzaSite</td>
    </tr>
    <tr>
      <td>All of our products, including AzaSite, are     subject to risks that are inherent to products based upon new <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>These risks include the risks that our products:       ·     are found to be unsafe or in<font color="blue">effective</font>;       ·     fail to receive <font color="blue">necessary</font> marketing clearance from <font color="blue">regulatory</font> authorities;       ·     even if safe and <font color="blue">effective</font>, are too <font color="blue">difficult</font> or expensive to <font color="blue">manufacture</font> or     market;       ·     are <font color="blue">unmarketable due</font> to the <font color="blue">proprietary</font> rights of <font color="blue">third parties</font>; or       ·     are not able to <font color="blue">compete with</font> superior, equivalent, more cost-<font color="blue">effective</font> or     more <font color="blue">effective</font>ly promoted products offered by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Therefore, our research and <font color="blue">development</font> <font color="blue">activities</font> including <font color="blue">with respect</font> to     AzaSite may not result in any <font color="blue"><font color="blue">commercially</font> viable products</font></td>
    </tr>
    <tr>
      <td>We have a history of operating losses and we expect to continue to have     losses in the future        We have incurred <font color="blue">significant</font> operating <font color="blue">losses since</font> our inception in 1986     and have pursued numerous drug <font color="blue">development</font> <font color="blue">candidates</font> that did not prove to     have <font color="blue">commercial potential</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our <font color="blue">accumulated deficit</font>     was <font color="blue">approximately</font> dlra136dtta5 million</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur net losses</font> for the     <font color="blue">foreseeable future</font> or until we are able to achieve <font color="blue">significant</font> royalties or     other <font color="blue">revenues from</font> sales of our products</td>
    </tr>
    <tr>
      <td>In addition, we recognize revenue     when all services have been performed and <font color="blue">collectibility</font> is <font color="blue">reasonably</font>     assured</td>
    </tr>
    <tr>
      <td>Accordingly, revenue for the sales of OcuGene may be recognized in     a <font color="blue">later period than</font> the <font color="blue">associated recognition</font> of costs of the services     provided, especially during the <font color="blue">initial launch</font> of the product</td>
    </tr>
    <tr>
      <td>In addition,     due to this delay in <font color="blue">revenue recognition</font>, our revenues recognized in any     <font color="blue">given period may</font> not be <font color="blue">indicative</font> of our <font color="blue">then current viability</font> and market     <font color="blue">acceptance</font> of our OcuGene product</td>
    </tr>
    <tr>
      <td><font color="blue">Attaining </font><font color="blue">significant</font> revenue or <font color="blue">profitability</font> <font color="blue">depends upon</font> our ability,     alone or with <font color="blue">third parties</font>, to develop our <font color="blue"><font color="blue">potential product</font>s</font> successfully,     conduct  clinical  trials,  obtain  required  <font color="blue"><font color="blue">regulatory</font> approvals</font> and     <font color="blue">manufacture</font> and market our <font color="blue">products successfully</font></td>
    </tr>
    <tr>
      <td>We may not ever achieve or     be able to maintain <font color="blue">significant</font> revenue or <font color="blue">profitability</font>, including with     respect to our leading <font color="blue">product candidate</font> AzaSite</td>
    </tr>
    <tr>
      <td>We may not <font color="blue">successfully manage</font> our growth        If  we  are able to raise <font color="blue"><font color="blue">additional</font> funding</font> and gain FDA approval for     <font color="blue">additional</font> products, including AzaSite, our success will <font color="blue">depend upon</font> the     expansion of our <font color="blue">operations</font> and the <font color="blue">effective</font> <font color="blue">management</font> of our growth,     which  will  place  a  <font color="blue">significant</font> strain on our <font color="blue">management</font> and on our     <font color="blue">administrative</font>, operational and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>To manage this growth,     we will have to expand our <font color="blue">facilities</font>, augment our operational, financial     and <font color="blue">management</font> systems and hire and train <font color="blue">additional</font> qualified personnel</td>
    </tr>
    <tr>
      <td>If     we  are unable to manage our growth <font color="blue">effective</font>ly, our business would be     harmed</td>
    </tr>
    <tr>
      <td>Our products are subject to <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font> and <font color="blue">approvals which may</font>     delay or prevent the marketing of <font color="blue"><font color="blue">potential product</font>s</font> and <font color="blue">impose costly</font>     <font color="blue">procedures upon</font> our <font color="blue">activities</font>        The FDA and comparable agencies in state and local <font color="blue">jurisdictions</font> and in     <font color="blue">foreign countries impose</font> substantial <font color="blue"><font color="blue">requirements</font> upon preclinical</font> and     <font color="blue">clinical testing</font>, <font color="blue">manufacturing</font> and marketing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td><font color="blue">Lengthy  </font>and  detailed preclinical and <font color="blue">clinical testing</font>, <font color="blue">validation</font> of     <font color="blue">manufacturing</font>  and  quality  control  processes,  and other costly and     time-consuming procedures are required</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of these <font color="blue">requirements</font>     typically takes several years and the time needed to <font color="blue">satisfy them may vary</font>     <font color="blue">substantially</font>,  based  on  the  type,  <font color="blue">complexity</font>  and  novelty of the     <font color="blue">pharmaceutical</font> product</td>
    </tr>
    <tr>
      <td>The effect of <font color="blue"><font color="blue">government</font> regulation may</font> be to delay     or to <font color="blue">prevent marketing</font> of <font color="blue"><font color="blue">potential product</font>s</font> for a considerable period of     time and to <font color="blue">impose costly</font> <font color="blue">procedures upon</font> our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The FDA or any     other <font color="blue">regulatory</font> agency may not <font color="blue">grant approval on</font> a <font color="blue">timely basis</font>, or at all,     for any products we develop</td>
    </tr>
    <tr>
      <td>Data obtained     from  preclinical  and  clinical <font color="blue">activities</font> are susceptible to varying     <font color="blue">interpretations</font> that <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>If     <font color="blue">regulatory</font>  approval of a product is granted, such approval may impose     <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which a <font color="blue">product may</font> be marketed</td>
    </tr>
    <tr>
      <td>Further, even after we have obtained <font color="blue">regulatory</font> approval, later discovery of     <font color="blue">previously unknown problems with</font> a <font color="blue">product may</font> result in <font color="blue"><font color="blue">restrictions</font> on</font> the     product, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Moreover, the     FDA has recently reduced previous <font color="blue"><font color="blue">restrictions</font> on</font> the marketing, sale and     <font color="blue">prescription</font> of products for <font color="blue">indications</font> other than those <font color="blue">specifically</font>     <font color="blue">approved by</font> the FDA Accordingly, even if we receive FDA approval of a     product  for  certain  indicated  uses, our <font color="blue">competitors</font>, including our     <font color="blue">collaborators</font>, could market products for such <font color="blue">indications</font> even if such     products  have  not  been  <font color="blue">specifically</font> approved for such <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Additionally, the FDA <font color="blue">recently issued</font> an advisory that <font color="blue">microarrays used</font> for     <font color="blue">diagnostic</font> and <font color="blue">prognostic testing may</font> need <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>The need for     <font color="blue">regulatory</font> approval of <font color="blue">multiple gene analysis</font> is <font color="blue">uncertain at</font> this time</td>
    </tr>
    <tr>
      <td>Delay in obtaining or failure to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> would make it     <font color="blue">difficult</font> or impossible to market our products and would harm our business,     prospects, financial condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       The FDA’s <font color="blue">policies may</font> change and <font color="blue">additional</font> <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font> may be     promulgated  which  could  prevent or delay <font color="blue">regulatory</font> approval of our     <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Moreover, increased attention to the <font color="blue">containment</font> of     health  <font color="blue">care costs</font> in the <font color="blue"><font color="blue">United States</font> </font>could result in <font color="blue">new <font color="blue">government</font></font>     <font color="blue">regulations</font> that <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue"><font color="blue"><font color="blue">government</font>al</font> regulation</font>     might arise <font color="blue">from future <font color="blue">legislative</font></font> or <font color="blue">administrative</font> action, either in the     <font color="blue"><font color="blue">United States</font> </font>or abroad</td>
    </tr>
    <tr>
      <td>See “-<font color="blue">Uncertainties </font>regarding <font color="blue">healthcare reform</font> and     third-party <font color="blue">reimbursement</font> may impair our ability to <font color="blue">raise capital</font>, form     <font color="blue">collaboration</font>s and sell our products”       We have no experience in performing the <font color="blue">analytical procedures</font> related to     genetic testing and have established an exclusive commercial <font color="blue">agreement</font> with     a <font color="blue">third party</font> to perform these procedures for our OcuGene <font color="blue">glaucoma genetic</font>     test; If we are unable to maintain this <font color="blue">arrangement</font>, and are unable to     establish new <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font>, we will have to establish our     own <font color="blue">regulatory</font> compliant analytical process for genetic testing and may not     have the <font color="blue">financial resources</font> to do so        We  have no experience in the <font color="blue">analytical procedures</font> related to genetic     testing</td>
    </tr>
    <tr>
      <td>We  have  entered  into  an <font color="blue">agreement</font> with Quest Diagnostics     Incorporated  under  which  Quest <font color="blue">exclusively</font> performs OcuGene genetic     analytical  procedures  at  a  commercial  scale in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are <font color="blue">reliant on</font> Quest for all of our OcuGene analytical     procedures</td>
    </tr>
    <tr>
      <td>If we are unable to maintain this <font color="blue">arrangement</font>, we would have to     <font color="blue">contract with</font> another <font color="blue">clinical <font color="blue">laboratory</font></font> or would have to establish our own     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to <font color="blue">contract with</font>     another <font color="blue">laboratory</font> to perform these <font color="blue">services on</font> a <font color="blue"><font color="blue">commercially</font> reasonable</font>     basis, or at all</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">laboratories must adhere</font> to <font color="blue">Good Laboratory Practice </font><font color="blue">regulations</font>     that are <font color="blue">strictly enforced by</font> the FDA on an <font color="blue"><font color="blue">ongoing basis</font> through</font> the FDA’s     <font color="blue">facilities</font>  inspection  program</td>
    </tr>
    <tr>
      <td>Should we be required to perform the     <font color="blue">analytical procedures</font> for <font color="blue">genetic testing ourselves</font>, we:       ·     will be required to expend <font color="blue">significant</font> amounts of capital to install an     <font color="blue">analytical capability</font>;       ·     will be subject to the <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> described above; and       ·     will require <font color="blue">substantially</font> more <font color="blue">additional</font> capital than we <font color="blue">otherwise may</font>     require</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you we will be <font color="blue">able successfully</font> to <font color="blue">enter into</font> another     genetic testing <font color="blue">arrangement</font> or perform these <font color="blue">analytical procedures</font> ourselves     on a cost-efficient basis, or at all</td>
    </tr>
    <tr>
      <td>We rely on a sole source for some of the <font color="blue">raw materials</font> in our products,     including AzaSite, and the <font color="blue">raw materials</font> we need may not be available to us        We  currently have a <font color="blue">single supplier</font> for <font color="blue">azithromycin</font>, the <font color="blue">active drug</font>     <font color="blue">incorporated into</font> our AzaSite <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>The supplier has submitted     a <font color="blue">Drug Master File </font>on the <font color="blue">compound with</font> the FDA and is subject to the FDA’s     review and oversight</td>
    </tr>
    <tr>
      <td>If this supplier failed or refused to continue to     supply us, the FDA were to identify issues in the production of the drug     that the supplier was unable to <font color="blue">resolve quickly</font>, or other issues were to     arise that <font color="blue">impact production</font>, our ability to continue the <font color="blue">development</font> of     AzaSite, and <font color="blue">potentially</font> the <font color="blue">commercial sale</font> if the product is approved,     could be <font color="blue">interrupted</font>, which would harm our business prospects</td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font>suppliers for this drug exist, <font color="blue">but <font color="blue">qualification</font></font> of an <font color="blue">alternative source</font>     could be time consuming, expensive and <font color="blue">could harm</font> our business and there is     no  guarantee  that  these  <font color="blue">additional</font> suppliers can <font color="blue">supply sufficient</font>     <font color="blue">quantities at</font> a <font color="blue">reasonable price</font>, or at all</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       SSP is the sole source for the <font color="blue">active drug</font> <font color="blue">incorporated into</font> the ISV-403     <font color="blue">product candidate</font> we sold to Bausch &amp; Lomb for further <font color="blue">development</font> and     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>SSP has submitted a <font color="blue">Drug Master File </font>on the <font color="blue">compound with</font>     the FDA and is subject to the FDA’s review and oversight</td>
    </tr>
    <tr>
      <td>If SSP is unable     to obtain and maintain FDA approval for their production of the drug or is     otherwise  unable or unwilling to supply Bausch &amp; Lomb <font color="blue">with sufficient</font>     quantities  of  the drug, Bausch &amp; Lomb’s ability to <font color="blue">continue with</font> the     <font color="blue">development</font>, and <font color="blue">potentially</font> the <font color="blue">commercial sale</font> if the product is approved,     of  ISV-403  would  be  <font color="blue">interrupted</font> or impeded, and our <font color="blue">royalties from</font>     <font color="blue">commercial sale</font>s of the ISV-403 <font color="blue">product could</font> be delayed or reduced and our     business could be harmed</td>
    </tr>
    <tr>
      <td>In addition, certain of the <font color="blue">raw materials</font> we use in <font color="blue">formulating</font> our <font color="blue">DuraSite     </font><font color="blue">drug delivery system</font> are <font color="blue">available on</font>ly from <font color="blue">Noveon Corporation</font></td>
    </tr>
    <tr>
      <td>Although we     do not have a current supply <font color="blue">agreement</font> with the <font color="blue">Noveon Corporation</font>, to date     we have not <font color="blue">encountered</font> any <font color="blue">difficult</font>ies obtaining <font color="blue">necessary</font> materials from     them</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> interruption in the supply of these <font color="blue">raw materials</font>     <font color="blue">could delay</font> our <font color="blue">clinical trials</font>, product <font color="blue">development</font> or <font color="blue">product sales</font> and     <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We  have  no  experience  in  commercial <font color="blue">manufacturing</font> and if contract     <font color="blue">manufacturing</font>  is  not  available to us or does not satisfy <font color="blue">regulatory</font>     <font color="blue">requirements</font>,  we  will have to establish our own <font color="blue">regulatory</font> compliant     <font color="blue">manufacturing</font> capability and may not have the <font color="blue">financial resources</font> to do so        We have no experience <font color="blue">manufacturing</font> products <font color="blue">for Phase </font>3 and commercial     purposes</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">pilot <font color="blue">facility</font> licensed by</font> the <font color="blue">State of California </font>to     <font color="blue">manufacture</font> a number of our products <font color="blue">for Phase </font>1 and Phase 2 <font color="blue">clinical trials</font>     but not for late stage <font color="blue">clinical trials</font> or <font color="blue">commercial purposes</font></td>
    </tr>
    <tr>
      <td>Any delays or     <font color="blue">difficult</font>ies  that  we <font color="blue">may encounter</font> in <font color="blue">establishing</font> and maintaining a     <font color="blue">relationship</font> with qualified <font color="blue">manufacture</font>rs to produce, package and distribute     our finished <font color="blue">products may</font> harm our <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> filings,     <font color="blue">market <font color="blue">introduction</font></font> and <font color="blue">subsequent sales</font> of our products</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">contract with</font> Cardinal Health, the <font color="blue">manufacture</font>r of our AzaSite     Phase 3 clinical trial supplies and <font color="blue">registration batches</font>, to validate their     <font color="blue">production line</font> for <font color="blue">commercial scale batches</font> and to <font color="blue">manufacture</font> the required     <font color="blue">validation</font> batches for FDA review</td>
    </tr>
    <tr>
      <td>Additionally, we have <font color="blue">entered into</font> a     commercial <font color="blue">manufacturing</font> <font color="blue">agreement</font> with <font color="blue">Cardinal Health </font>for an <font color="blue">initial four</font>     year period</td>
    </tr>
    <tr>
      <td>Other commercial <font color="blue">manufacture</font>rs exist and we currently believe     that  we could obtain alternative commercial <font color="blue">manufacturing</font> services if     required</td>
    </tr>
    <tr>
      <td>However, <font color="blue">qualification</font> of another <font color="blue">manufacture</font>r, transfer of the     <font color="blue">manufacturing</font> process and <font color="blue">regulatory</font> approval of such a site would be costly     and  time  consuming  and  <font color="blue">would adversely impact</font> our <font color="blue">potential market</font>     <font color="blue">introduction</font> and <font color="blue">subsequent sales</font> of AzaSite</td>
    </tr>
    <tr>
      <td>Cardinal Health’s <font color="blue">facility</font> and     the line that will be used to produce the AzaSite units will be subject to     <font color="blue">inspection by</font> the FDA prior to the approval of the related NDA that we     anticipate filing in 2006</td>
    </tr>
    <tr>
      <td>While we believe <font color="blue">Cardinal Health </font>will be prepared     for  the  <font color="blue">inspections</font>,  they could <font color="blue">encounter delays</font> or <font color="blue">difficult</font>ies in     preparing for, or during, the inspection which <font color="blue">would adversely impact</font> our     potential <font color="blue">market <font color="blue">introduction</font></font> and <font color="blue">subsequent sales</font> of AzaSite</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently <font color="blue">contract with</font></font> a <font color="blue">third party</font> to assemble the sample <font color="blue">collection</font>     kits used in our OcuGene <font color="blue"><font color="blue">glaucoma genetic</font> test</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">assembler should</font>     encounter <font color="blue">significant</font> delays or we have <font color="blue">difficult</font>y maintaining our existing     <font color="blue">relationship</font>, or in <font color="blue">establishing</font> a new one, our sales of this <font color="blue">product could</font>     be <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contract  </font><font color="blue">manufacture</font>rs  must  adhere  to <font color="blue">Good Manufacturing Practices     </font><font color="blue">regulations</font>  that are <font color="blue">strictly enforced by</font> the FDA on an <font color="blue">ongoing basis</font>     through the FDA’s <font color="blue">facilities</font> inspection program</td>
    </tr>
    <tr>
      <td>Contract <font color="blue">manufacturing</font>     <font color="blue">facilities</font> must pass a pre-approval plant inspection before the FDA will     approve a <font color="blue">new drug application</font></td>
    </tr>
    <tr>
      <td>Some of the material <font color="blue">manufacturing</font> changes     that occur after approval are also subject to FDA review and clearance or     approval</td>
    </tr>
    <tr>
      <td>The FDA or other <font color="blue">regulatory</font> agencies may not approve the process     or the <font color="blue">facilities</font> by which any of our <font color="blue">products may</font> be <font color="blue">manufacture</font>d</td>
    </tr>
    <tr>
      <td>Our     dependence on <font color="blue">third parties</font> to <font color="blue">manufacture</font> our <font color="blue">products may</font> harm our ability     to develop and deliver <font color="blue">products on</font> a timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>Should we     be required to <font color="blue">manufacture</font> <font color="blue">products ourselves</font>, we:           22       _________________________________________________________________           ·     will be required to expend <font color="blue">significant</font> amounts of capital to install a     <font color="blue">manufacturing</font> capability;       ·     will be subject to the <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> described above;       ·     will be subject to similar risks regarding delays or <font color="blue">difficult</font>ies     <font color="blue">encountered</font> in <font color="blue">manufacturing</font> any <font color="blue">such products</font>; and       ·     will require <font color="blue">substantially</font> more <font color="blue">additional</font> capital than we <font color="blue">otherwise may</font>     require</td>
    </tr>
    <tr>
      <td>Therefore, we may not be able to <font color="blue">manufacture</font> any <font color="blue">products successfully</font> or in     a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>We compete in highly <font color="blue">competitive</font> markets and our <font color="blue">competitors</font>’ financial,     technical, marketing, <font color="blue">manufacturing</font> and <font color="blue">human resources may surpass ours</font> and     limit our ability to develop and/or market our products and <font color="blue">technologies</font>        Our success <font color="blue">depends upon</font> developing and maintaining a <font color="blue">competitive</font> advantage     in the <font color="blue">development</font> of products and <font color="blue">technologies</font> in our areas of focus</td>
    </tr>
    <tr>
      <td>We     have  many  <font color="blue">competitors</font>  in  the  United  States and abroad, including     <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and other <font color="blue">companies with varying resources</font> and     degrees of <font color="blue">concentration</font> in the <font color="blue">ophthalmic market</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> have     <font color="blue">existing products</font> or products under <font color="blue">development</font> which may be <font color="blue">technically</font>     superior to ours or which may be <font color="blue">less costly</font> or more acceptable to the     market</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> obtain cost advantages, patent protection or     other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> that would block or limit our ability to     develop our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>from these companies is intense     and  is  expected to <font color="blue">increase as new products enter</font> the market and new     <font color="blue">technologies</font> become available</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font>     greater financial, technical, marketing, <font color="blue">manufacturing</font> and human resources     than we do, <font color="blue">particularly</font> in light of our <font color="blue">current financial</font> condition</td>
    </tr>
    <tr>
      <td>In     addition, they may succeed in developing <font color="blue">technologies</font> and products that are     more  <font color="blue">effective</font>,  safer, less expensive or otherwise more <font color="blue">commercially</font>     acceptable than any that we have or will develop</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> also     obtain <font color="blue">regulatory</font> approval for <font color="blue">commercialization</font> of their products more     <font color="blue">effective</font>ly or <font color="blue">rapidly than</font> we will</td>
    </tr>
    <tr>
      <td>If we decide to <font color="blue">manufacture</font> and market     our <font color="blue">products by ourselves</font>, we will be competing in areas in which we have     limited or no experience such as <font color="blue">manufacturing</font> efficiency and marketing     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>See “ - We may require <font color="blue">additional</font> licenses or be subject to     expensive and uncertain <font color="blue">patent <font color="blue">litigation</font></font> in order to sell AzaSite in the     US and/or Europe; We are aware that Pfizer has recently received patents     in the <font color="blue">US and Europe </font><font color="blue">which cover</font> the use of <font color="blue">azithromycin</font> in a topical     <font color="blue">formulation</font> to <font color="blue">treat bacterial</font> <font color="blue">infections</font> in the eye,” and “- We have no     experience in commercial <font color="blue">manufacturing</font> and need to establish <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">relationship</font>s</font> with <font color="blue">third parties</font>, and if contract <font color="blue">manufacturing</font> is not     available to us or does not satisfy <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>, we will have to     establish our own <font color="blue">regulatory</font> compliant <font color="blue">manufacturing</font> capability and may not     have the financia1 resources to do so</td>
    </tr>
    <tr>
      <td>”       If  we <font color="blue">cannot compete successfully</font> for market share against other drug     companies, we may not achieve sufficient <font color="blue">product revenues</font> and our business     will suffer        The  market  for  our  product  <font color="blue">candidates</font> is <font color="blue">characterized by intense</font>     <font color="blue">competition</font> and <font color="blue">rapid technological advances</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">product candidate</font>s     receive FDA approval, they will <font color="blue">compete with</font> a number of existing and future     drugs and therapies developed, <font color="blue">manufacture</font>d and <font color="blue">marketed by others</font></td>
    </tr>
    <tr>
      <td><font color="blue">Existing     </font>or future <font color="blue">competing products</font> may provide greater <font color="blue">therapeutic</font> convenience or     clinical or other benefits for a <font color="blue">specific indication than</font> our products, or     <font color="blue">may offer comparable performance at</font> a <font color="blue">lower cost</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">products fail</font> to     capture and maintain market share, we may not achieve <font color="blue">sufficient product</font>     revenues and our business will be harmed</td>
    </tr>
    <tr>
      <td>We  will compete against fully integrated <font color="blue">pharmaceutical</font> companies and     smaller  companies  that  are collaborating with larger <font color="blue">pharmaceutical</font>     companies, <font color="blue">academic institutions</font>, <font color="blue">government</font> agencies and other public and     <font color="blue">private research organizations</font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have products     <font color="blue">competitive</font> with AzaSite <font color="blue">already approved</font> or in <font color="blue">development</font>, including Zymar     and Ocuflox by Allergan, Vigamox and Ciloxan by Alcon, and Quixin by Johnson     &amp; Johnson</td>
    </tr>
    <tr>
      <td>In addition, many of these <font color="blue">competitors</font>, either alone or together     with their <font color="blue">collaborative</font> partners, operate <font color="blue">larger research</font> and <font color="blue">development</font>     programs and have <font color="blue">substantially</font> greater <font color="blue">financial resources</font> than we do, as     well as <font color="blue">significant</font>ly greater experience in:       ·     developing drugs;       ·     undertaking pre-<font color="blue">clinical testing</font> and human <font color="blue">clinical trials</font>;       ·     obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approvals</font> of drugs;           23       _________________________________________________________________           ·     <font color="blue">formulating</font> and <font color="blue">manufacturing</font> drugs;       ·     launching, marketing and <font color="blue">selling drugs</font>; and       ·     attracting qualified personnel, parties for <font color="blue"><font color="blue">acquisition</font>s</font>, joint ventures or     other <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>regarding <font color="blue">healthcare reform</font> and third-party <font color="blue">reimbursement</font> may     impair  our ability to <font color="blue">raise capital</font>, form <font color="blue">collaboration</font>s and sell our     products        The <font color="blue">continuing efforts</font> of <font color="blue"><font color="blue">government</font>al</font> and third-party payers to contain or     reduce the costs of <font color="blue">healthcare through various</font> means may harm our business</td>
    </tr>
    <tr>
      <td>For example, in some <font color="blue">foreign markets</font> the pricing or <font color="blue">profitability</font> of health     <font color="blue">care products</font> is subject to <font color="blue"><font color="blue">government</font> control</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, there     have been, and we expect <font color="blue">there will continue</font> to be, a number of federal and     state proposals to implement similar <font color="blue"><font color="blue">government</font> control</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">implementation</font>     or even the <font color="blue">announcement</font> of any of these <font color="blue">legislative</font> or <font color="blue">regulatory</font> proposals     or  reforms <font color="blue">could harm</font> our business by impeding our ability to achieve     <font color="blue">profitability</font>,  <font color="blue">raise capital</font> or form <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">availability</font> of <font color="blue">reimbursement</font> from third-party payers determines, in large     part, the demand for health<font color="blue">care products</font> in the <font color="blue"><font color="blue">United States</font> </font>and elsewhere</td>
    </tr>
    <tr>
      <td>Examples of such third-party payers are <font color="blue">government</font> and private insurance     plans</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of     newly approved health<font color="blue">care products</font>, and third-party payers are <font color="blue">increasingly</font>     <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>If we     succeed in <font color="blue">bringing one</font> or more products to the market, <font color="blue">reimbursement</font> from     third-party payers may not be available or may not be sufficient to allow us     to sell our <font color="blue">products on</font> a <font color="blue">competitive</font> or <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>Our  insurance coverage may not <font color="blue">adequately</font> cover our <font color="blue">potential product</font>     <font color="blue">liability</font> exposure        We  are  exposed  to <font color="blue">potential product</font> <font color="blue">liability</font> risks inherent in the     <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>, marketing and sale of human <font color="blue">therapeutic</font>     products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> insurance for the <font color="blue">pharmaceutical</font> industry is     <font color="blue">extremely expensive</font></td>
    </tr>
    <tr>
      <td>Although we believe our <font color="blue">current insurance coverage</font> is     adequate to <font color="blue">cover likely</font> claims we <font color="blue">may encounter</font> given our <font color="blue">current stage</font> of     <font color="blue">development</font> and <font color="blue">activities</font>, our present product <font color="blue">liability</font> insurance coverage     may not be adequate to cover all potential claims we <font color="blue">may encounter</font></td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">existing coverage will</font> not be <font color="blue">adequate as</font> we further develop,     <font color="blue">manufacture</font> and market our products, and we may not be able to obtain or     <font color="blue">afford adequate insurance coverage against potential</font> claims in sufficient     amounts or at a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>Our use of <font color="blue"><font color="blue">hazardous</font> materials may pose environmental risks</font> and <font color="blue">liabilities</font>     which may cause us to incur <font color="blue">significant</font> costs        Our research, <font color="blue">development</font> and <font color="blue">manufacturing</font> processes involve the controlled     use  of  small  amounts  of  <font color="blue"><font color="blue">hazardous</font> solvents used</font> in <font color="blue">pharmaceutical</font>     <font color="blue">development</font> and <font color="blue">manufacturing</font>, including acetic acid, acetone, acrylic acid,     calcium chloride, chloroform, dimethyl sulfoxide, ethyl alcohol, hydrogen     chloride, nitric acid, phosphoric acid and other similar solvents</td>
    </tr>
    <tr>
      <td>We retain     a <font color="blue">licensed <font color="blue">outside contractor</font></font> that <font color="blue">specializes</font> in the disposal of <font color="blue">hazardous</font>     materials used in the bio<font color="blue">technology</font> industry to <font color="blue">properly dispose</font> of these     materials,  but  we <font color="blue">cannot completely eliminate</font> the risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>Our cost for the disposal     services rendered by our <font color="blue">outside contractor</font> was <font color="blue">approximately</font> dlra7cmam100 and     dlra10cmam400 for the years ended 2005 and 2004, respectively</td>
    </tr>
    <tr>
      <td>In the event of an     <font color="blue">accident involving</font> these materials, we could be held liable for any damages     that result, and any such <font color="blue">liability</font> could exceed our resources</td>
    </tr>
    <tr>
      <td>Moreover, as     our business develops we may be required to incur <font color="blue">significant</font> costs to     <font color="blue"><font color="blue">comply with</font> federal</font>, state and local environmental laws, <font color="blue">regulations</font> and     policies, especially to the extent that we <font color="blue">manufacture</font> our own products</td>
    </tr>
    <tr>
      <td>If we engage in <font color="blue"><font color="blue">acquisition</font>s</font>, we will incur a variety of costs, and the     anticipated benefits of the <font color="blue"><font color="blue">acquisition</font> may never</font> be realized        We may pursue <font color="blue"><font color="blue">acquisition</font>s</font> of companies, product lines, <font color="blue">technologies</font> or     <font color="blue">businesses</font> that our <font color="blue">management</font> believes are <font color="blue">complementary</font> or otherwise     <font color="blue">beneficial</font> to us</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue"><font color="blue">acquisition</font>s</font> could have a negative effect on     our business</td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">acquisition</font>s</font> may result in substantial dilution to our     <font color="blue">stockholders</font>, the incurrence of <font color="blue">additional</font> debt and <font color="blue">amortization expenses</font>     related to goodwill, research and <font color="blue">development</font> and other <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">acquisition</font>s</font> would involve several risks for us, including:               24       _________________________________________________________________           ·     assimilating employees, <font color="blue">operations</font>, <font color="blue">technologies</font> and products from the     acquired companies with our existing employees, <font color="blue">operations</font>, <font color="blue">technologies</font> and     products;       ·     diverting our <font color="blue">management</font>’s attention from day-to-day operation of our     business;       ·     <font color="blue">entering markets</font> in which we have no or limited direct experience; and       ·     <font color="blue">potentially</font> losing <font color="blue">key employees</font> from the acquired companies</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>and principal <font color="blue">stockholders</font> may be able to exert <font color="blue">significant</font>     control on matters requiring approval by our <font color="blue">stockholders</font> and security     interests in our assets held by <font color="blue">management</font> may enable them to control the     <font color="blue">disposition</font> of such assets        As of <font color="blue">December </font>31, 2005, our <font color="blue">management</font> and principal <font color="blue">stockholders</font> together     <font color="blue">beneficial</font>ly owned <font color="blue">approximately</font> 19prca of our <font color="blue">outstanding shares</font> of Common     Stock</td>
    </tr>
    <tr>
      <td>In addition, investors in our March/June 2004 and May 2005 private     placements, as a group, owned <font color="blue">approximately</font> 42prca of our <font color="blue">outstanding shares</font> of     <font color="blue">Common Stock</font> as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If <font color="blue">such investors</font> were to exercise the     warrants  they  currently hold, assuming no <font color="blue">additional</font> <font color="blue"><font color="blue">acquisition</font>s</font> or     <font color="blue">distribution</font>s, <font color="blue">such investors</font> would own <font color="blue">approximately</font> 54prca of our outstanding     shares of <font color="blue">Common Stock</font> <font color="blue">based on</font> their <font color="blue">ownership percentages as</font> of <font color="blue">December </font>    31, 2005</td>
    </tr>
    <tr>
      <td>As a result, these two groups of <font color="blue">stockholders</font>, acting together or     as individual groups, may be able to exert <font color="blue">significant</font> control on matters     requiring approval by our <font color="blue">stockholders</font>, including the election of all or at     least a majority of our <font color="blue">Board of Directors</font>, <font color="blue">amendments</font> to our charter, and     the approval of business <font color="blue">combinations</font> and <font color="blue">certain financing transactions</font></td>
    </tr>
    <tr>
      <td>Chandrasekaran, our <font color="blue"><font color="blue">chief executive</font> officer</font>, chief financial officer and     a member of our <font color="blue">Board of Directors</font>, for cash</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005,     dlra231cmam000 in <font color="blue">principal amount remained outstanding</font></td>
    </tr>
    <tr>
      <td>This note bears an annual     interest rate of five and one-half percent (5dtta5prca) and is due on the earlier     to occur of March 31, 2007 and upon an event that triggers a Mandatory     Redemption of the notes issued in the offering of our Senior Secured Notes,     and is <font color="blue">secured by</font> a lien on all of our assets including our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Senior Secured Notes </font>are <font color="blue">secured by</font> a lien on all     of our assets and are <font color="blue">on parity with</font> the note issued to our <font color="blue">chief executive</font>     officer</td>
    </tr>
    <tr>
      <td>These <font color="blue">security interest</font>s will enable the holders of the <font color="blue">Senior Secured Notes </font>    to  control  the  <font color="blue">disposition</font> of all of our assets in the event of our     <font color="blue">liquidation</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable  to repay the <font color="blue">amounts due under</font> this     indebtedness, such secured lenders could cause us to <font color="blue">enter into</font> <font color="blue">involuntary</font>     <font color="blue">liquidation</font> <font color="blue">proceedings</font> in the event we <font color="blue">default on</font> our <font color="blue">obligations</font> and take     possession of our assets</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies such as ours have been and are likely to continue to be highly     <font color="blue">volatile due</font> to reasons that are related and unrelated to our operating     performance and progress        The <font color="blue">market price</font>s for securities of bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies, including ours, have <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>The market has from     time to time experienced <font color="blue">significant</font> price and <font color="blue">volume <font color="blue">fluctuations</font></font> that are     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>In addition,     future  <font color="blue">announcement</font>s and <font color="blue">circumstances</font>, such as our <font color="blue">current financial</font>     condition, the audit report included in our annual report on Form 10-K for     the year ended <font color="blue">December </font>31, 2004 that includes an <font color="blue"><font color="blue">explanatory</font> paragraph</font>     referring to our recurring operating losses and a substantial <font color="blue">doubt about</font>     our  ability to <font color="blue">continue as</font> a going concern, our ability to obtain new     financing, the terms of any financing we are able to raise, the results of     testing and <font color="blue">clinical trials</font>, <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font>     rights of us or our <font color="blue">competitors</font>, <font color="blue">litigation</font> regarding the same, the status     of  our  <font color="blue"><font color="blue">relationship</font>s</font>  with  third-party <font color="blue">collaborators</font>, technological     <font color="blue">innovations</font> or new <font color="blue">therapeutic</font> products, <font color="blue"><font color="blue"><font color="blue">government</font>al</font> regulation</font>, or public     concern as to the safety of products developed by us or others and general     market <font color="blue">conditions</font>, <font color="blue">concerning</font> us, our <font color="blue">competitors</font> or other bio<font color="blue">pharmaceutical</font>     companies, may have a <font color="blue">significant</font> effect on the <font color="blue">market price</font> of our Common     Stock</td>
    </tr>
    <tr>
      <td>In addition, terrorist attacks <font color="blue">in the US </font>and abroad, US <font color="blue">retaliation</font> for     these attacks, the war in Iraq and continued worldwide economic weakness and     the related decline in consumer confidence have had, and may continue to     have, an adverse impact on the US and world economy</td>
    </tr>
    <tr>
      <td>These and similar     events,  as  well  as <font color="blue">fluctuations</font> in our operating results and market     <font color="blue">conditions</font> for bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> stocks in general, could     have a <font color="blue">significant</font> effect on the <font color="blue">volatility</font> of the <font color="blue">market price</font> for our     <font color="blue">Common Stock</font> and on the future price of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       The exercise of <font color="blue">outstanding warrants</font> and the sale of the shares of our     <font color="blue">Common Stock</font> <font color="blue">issuable upon exercise</font> of those <font color="blue">outstanding warrants</font> could     result  in dilution to our <font color="blue">current holders</font> of <font color="blue">Common Stock</font> and cause a     <font color="blue">significant</font> decline in the <font color="blue">market price</font> for our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>We have not     paid any <font color="blue">cash <font color="blue">dividends on</font></font> our <font color="blue">Common Stock</font>, and we do not anticipate paying     any <font color="blue">dividends on</font> our <font color="blue">Common Stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font> with our <font color="blue">December </font>2005/<font color="blue">January </font>2006 Private Placement of Notes     and Warrants, we issued Warrants to purchase 1cmam460cmam000 shares of our Common     Stock</td>
    </tr>
    <tr>
      <td>The issuance of these shares of <font color="blue">Common Stock</font> will be dilutive to our     current <font color="blue">stockholders</font> and <font color="blue">could <font color="blue">adversely affect</font></font> the <font color="blue">market price</font> for our     <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>We have adopted and are subject to anti-takeover provisions that <font color="blue">could delay</font>     or prevent an <font color="blue">acquisition</font> of our Company and could prevent or make it more     <font color="blue">difficult</font> to replace or remove current <font color="blue">management</font>        <font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws may constrain or     discourage a <font color="blue">third party</font> from acquiring or attempting to acquire control of     us</td>
    </tr>
    <tr>
      <td>Such <font color="blue">provisions could limit</font> the price that investors might be willing to     pay  in  the  future for shares of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>In addition, such     <font color="blue">provisions could also prevent</font> or make it more <font color="blue">difficult</font> for our <font color="blue">stockholders</font>     to replace or remove current <font color="blue">management</font> and <font color="blue">could <font color="blue">adversely affect</font></font> the price     of our <font color="blue">Common Stock</font> if they are viewed <font color="blue">as discouraging <font color="blue">takeover attempt</font>s</font>,     business <font color="blue">combinations</font> or <font color="blue">management</font> changes that <font color="blue">stockholders</font> consider in     their <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">Board of Directors</font> </font>has the authority to issue up to     5cmam000cmam000 shares of <font color="blue">preferred stock</font> (“Preferred Stock”), 15cmam000 of which     have <font color="blue">been designated as</font> Series A-1 Preferred Stock</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">Board of Directors</font> </font>    has the authority to determine the price, rights, preferences, privileges     and <font color="blue">restrictions</font>, including <font color="blue">voting rights</font>, of the <font color="blue">remaining unissued shares</font>     of <font color="blue">Preferred Stock </font>without any <font color="blue">further vote</font> or <font color="blue">action by</font> the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of <font color="blue">Common Stock</font> will be subject to, and may be     <font color="blue"><font color="blue">adversely affect</font>ed</font> by, the rights of the holders of any <font color="blue">Preferred Stock </font>that     may  be  issued  in the future</td>
    </tr>
    <tr>
      <td>The issuance of Preferred Stock, while     <font color="blue">providing desirable flexibility</font> in <font color="blue">connection</font> with possible <font color="blue">financings</font>,     <font color="blue"><font color="blue">acquisition</font>s</font> and other corporate purposes, could have the effect of making     it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our outstanding     voting stock, even if the <font color="blue">transaction might</font> be desired by our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of <font color="blue">Delaware </font><font color="blue">law applicable</font> to <font color="blue">us could also delay</font> or make more     <font color="blue">difficult</font> a merger, tender offer or <font color="blue">proxy contest involving us</font>, including     Section 203 of the <font color="blue">Delaware </font>General Corporation Law, <font color="blue">which prohibits</font> a     <font color="blue">Delaware </font><font color="blue">corporation from</font> engaging in any business <font color="blue">combination with</font> any     <font color="blue">interested stockholder</font> for a period of three years unless <font color="blue">conditions</font> set     forth in the <font color="blue">Delaware </font>General Corporation Law are met</td>
    </tr>
    <tr>
      <td>The issuance of     <font color="blue">Preferred Stock </font>or Section 203 of the <font color="blue">Delaware </font>General Corporation Law could     also  be  deemed  to  benefit incumbent <font color="blue">management</font> to the extent these     provisions  deter  <font color="blue">offers by persons</font> who would wish to make changes in     <font color="blue">management</font> or exercise control over <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Other provisions of our     <font color="blue">certificate</font>  of  <font color="blue">incorporation</font>  and <font color="blue">bylaws may also</font> have the effect of     delaying, deterring or preventing a <font color="blue">takeover attempt</font> or <font color="blue">management</font> changes     that our <font color="blue">stockholders</font> might consider in their <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>For example,     our <font color="blue">bylaws limit</font> the ability of <font color="blue">stockholders</font> to <font color="blue">remove <font color="blue">directors</font></font> and fill     <font color="blue">vacancies on</font> our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">bylaws also impose advance</font> notice     <font color="blue">requirements</font> for <font color="blue">stockholder proposals</font> and <font color="blue">nominations</font> of <font color="blue">directors</font> and     prohibit <font color="blue">stockholders</font> from calling special meetings or acting by written     consent</td>
    </tr>
    <tr>
      <td><font color="blue">Legislative </font>actions, higher insurance costs and potential new <font color="blue">accounting</font>     <font color="blue">pronouncements</font>  are likely to impact our future financial position and     results of <font color="blue">operations</font>        There have been <font color="blue">regulatory</font> changes, including the Sarbanes-Oxley Act of     2002, and there may be potential new <font color="blue">accounting</font> <font color="blue">pronouncements</font> or <font color="blue">regulatory</font>     rulings, which will have an impact on our future financial position and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 and other rule changes     and proposed <font color="blue">legislative</font> initiatives are likely to <font color="blue">increase general</font> and     <font color="blue">administrative</font>  costs</td>
    </tr>
    <tr>
      <td>In addition, insurance costs, including health,     workers’ compensation and <font color="blue">directors</font> and officers’ insurance costs, have been     <font color="blue">dramatically increasing</font> and insurers are likely to <font color="blue">increase rates as</font> a     result of high claims <font color="blue">rates over</font> the past year and our rates are likely to     <font color="blue">increase further</font> in the future</td>
    </tr>
    <tr>
      <td>Further, initiatives could result in changes     in <font color="blue">accounting</font> rules, including <font color="blue">legislative</font> and other proposals to account     for <font color="blue">employee stock options as</font> an expense</td>
    </tr>
    <tr>
      <td>These and other potential changes     <font color="blue">could materially increase</font> the expenses we report <font color="blue">under generally accepted</font>     <font color="blue">accounting</font> principles, and <font color="blue">adversely affect</font> our operating results</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________       We may not be able to make principal or <font color="blue">interest payments</font> on our Senior     Secured Notes        The  Senior  Secured Notes are <font color="blue">secured by</font> a lien on all of our assets,     including our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Under our Senior Secured Notes, dlra4dtta3     million in <font color="blue">aggregate principal amount</font> has an <font color="blue">initial maturity date</font> of <font color="blue">June     </font>30, 2006, which may be extended, at our option, until <font color="blue">December </font>30, 2006</td>
    </tr>
    <tr>
      <td>In     addition,  dlra2dtta0 million in <font color="blue">aggregate principal amount</font> under the Senior     Secured Notes has an <font color="blue">initial maturity date</font> of July 11, 2006, which may be     extended, at our option, until <font color="blue">January </font>11, 2007</td>
    </tr>
    <tr>
      <td>If we are unable to enter     into <font color="blue">additional</font> corporate <font color="blue">collaboration</font>s, close equity or debt <font color="blue">financings</font> or     <font color="blue">generate sufficient cash flow from</font> our <font color="blue">operations</font> and are <font color="blue">otherwise unable</font>     to  obtain  funds <font color="blue">necessary</font> to meet required payments of principal and     <font color="blue">interest on</font> our <font color="blue">Senior Secured Notes </font>by <font color="blue">December </font>30, 2006 and <font color="blue">January </font>11,     2007, we would be in <font color="blue">default under</font> the terms of such notes</td>
    </tr>
    <tr>
      <td>In the event of     such a payment or other event of default, the holders of the Senior Secured     Notes (as well as the holders of our other secured indebtedness) could elect     to declare all the <font color="blue">funds borrowed thereunder</font> to be due and payable, together     with accrued and <font color="blue">unpaid interest</font>, and institute foreclosure <font color="blue">proceedings</font>     against our assets, and we could be forced into <font color="blue">bankruptcy</font> or <font color="blue">insolvency</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Because the holders of the <font color="blue">Senior Secured Notes </font>have a senior     security  interest in all of our assets, they will have the ability to     control the <font color="blue">liquidation</font> of our assets and will have <font color="blue">first priority on</font> any     <font color="blue">funds generated therefrom</font></td>
    </tr>
    <tr>
      <td>Our common <font color="blue">stockholders</font> will likely not receive     any <font color="blue">proceeds from such</font> a <font color="blue">liquidation</font></td>
    </tr>
    <tr>
      <td>Even if we are successful in raising     <font color="blue">additional</font> funds, we may be forced to curtail our operating <font color="blue">activities</font> in     order to meet our <font color="blue">obligations</font> under the <font color="blue">Senior Secured Notes </font><font color="blue">which could</font>     harm our business and prospects</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Senior Secured Notes </font><font color="blue">contain various negative covenants</font>,     including covenants that <font color="blue">prevent us from incurring indebtedness</font> in excess of     dlra100cmam000,  granting  liens  on our assets or <font color="blue">repurchasing</font> or declaring     <font color="blue">dividends on</font> our <font color="blue">equity securities</font>, any of <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td>In     addition to limiting our ability to operate our business, a failure to     <font color="blue">comply with</font> these <font color="blue">covenants would lead</font> to a <font color="blue">default under</font> the notes and an     <font color="blue">acceleration</font> of the outstanding <font color="blue">amounts due under</font> the notes</td>
    </tr>
    <tr>
      <td>If this were to     occur we can make no assurance that we would have <font color="blue">sufficient funds</font> to repay     the notes, <font color="blue">which could</font> result in foreclosure <font color="blue">proceedings</font> against our assets     or <font color="blue">bankruptcy</font> or <font color="blue">insolvency</font> <font color="blue">proceedings</font></td>
    </tr>
  </tbody>
</table>